Tivoxen 1.34 mg Capsule

Description

Tivoxen Capsule contains Tivozanib, a targeted anti-cancer medicine used for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), specifically designed to block tumor growth by targeting blood vessel formation. Cancer cells require a continuous blood supply to grow and spread. Tivoxen works by inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are responsible for the formation of new blood vessels (angiogenesis). By blocking these receptors, the medicine effectively reduces blood supply to tumors, slowing their growth and progression. Tivoxen is typically prescribed for patients whose cancer has progressed after receiving previous treatments. It is taken orally, making it a convenient alternative to injectable cancer therapies. Clinical studies

Benefits

• Targets cancer growth at the molecular level
• Slows tumor progression by blocking blood supply
• Improves progression-free survival in RCC patients
• Oral therapy (more convenient than IV treatments)
• Effective in patients with treatment-resistant cancer

Indications and Usage

Tivoxen (Tivozanib) is indicated for:

• Advanced renal cell carcinoma (kidney cancer)
• Relapsed or refractory RCC after prior treatments
• Patients who have received two or more systemic therapies

How it Works

Tivozanib works by targeting specific proteins involved in tumor growth:

• Inhibits VEGFR receptors (key drivers of angiogenesis)
• Prevents formation of new blood vessels supplying tumors
• Reduces tumor growth and spread

This targeted mechanism helps control cancer progression more precisely.

Dosage & Administration

• Typical dose: 1.34 mg once daily
• Taken for 21 days followed by 7 days off (28-day cycle)
• Continue until disease progression or unacceptable toxicity
• Can be taken with or without food
• Capsules must be swallowed whole

Side Effects

Common side effects:

• High blood pressure (hypertension)
• Fatigue
• Diarrhea
• Decreased appetite
• Nausea

Serious side effects:

• Severe hypertension or hypertensive crisis
• Heart problems (cardiac failure)
• Blood clots
• Bleeding complications
• Protein in urine (proteinuria)

Patients should be closely monitored during treatment.

Warning and Precaution

• Monitor blood pressure regularly
• Risk of heart-related complications
• Avoid use during pregnancy (may harm fetus)
• Monitor kidney and liver function
• Risk of bleeding and clotting disorders
• Avoid drug interactions (e.g., herbal supplements like St. John’s Wort)

Patient Guidance

• Take the medicine at the same time every day
• Do not skip doses or double dose
• Monitor blood pressure regularly
• Report symptoms like severe headache, chest pain, or bleeding
• Attend regular follow-up and blood tests
• Avoid pregnancy during treatment

Clinical Trial & Approvals

Tivozanib is a globally recognized oncology drug:

• Approved in the European Union (2017) and USA (2021)
• Based on Phase III trials comparing it with other cancer therapies
• Demonstrated improvement in progression-free survival in RCC patients
• Studied in multiple international clinical trials

References

1. Tivozanib drug information (MedlinePlus)
➤ https://medlineplus.gov/druginfo/meds/a621018.html

2. Tivoxen product overview
➤ https://oncosolution.com/oncology/tivoxen-134-mg-tivozanib-capsule/

3. Tivozanib dosage & mechanism (SK Pharma)
➤ https://www.skpharmabd.com/product/tivoxen-1-34-mg-tivozanib/

4. Tivozanib clinical overview (Cleveland Clinic)
➤ https://my.clevelandclinic.org/health/drugs/23896-tivozanib-oral-capsules

5. Tivozanib clinical data & approval (Wikipedia)
➤ https://en.wikipedia.org/wiki/Tivozanib